AAX Featured in INNOVATE™ Stockholm

We are pleased to share that AAX Biotech has been featured in INNOVATE™ Stockholm for our work on pioneering the next wave of precision antibody therapeutics and as a member of Stockholm’s vibrant life sciences hub. 

“These technologies were born out of necessity,” — Daniel X Johansson, CSO and Co-Founder. 

“By providing high-resolution insights into antibody behaviour, we enable our partners to accelerate and de-risk their development pipelines.” — Maria Lisa Knudsen, CEO 

With our proprietary platforms — Seqitope®, for high-resolution epitope mapping, and Opti-mAb®, for stabilizing and optimizing antibody fragments — we are building cutting-edge technologies that will bring next-generation antibody drugs with great therapeutic impact closer to patients.